Ribavirin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ribavirin: From Chronic Hepatitis C to Chronic Hepatitis B Virus Infection
One-Sentence Summary
Ribavirin is a guanosine-analog antiviral, established clinically in combination with peginterferon for chronic hepatitis C (HCV). The TxGNN model predicts it may be effective for Chronic Hepatitis B Virus Infection, with 63 clinical trials and 20 publications retrieved as candidate evidence — however, close review shows most of this evidence actually describes HCV or HCV/HBV co-infection, not HBV monoinfection, and the signal likely reflects knowledge-graph node proximity rather than a genuine mechanistic finding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Hepatitis C (HCV), in combination with peginterferon (TFDA-approved indication text unavailable — see Data Gap DG001) |
| Predicted New Indication | Chronic Hepatitis B Virus Infection |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L2 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed formal MOA data from DrugBank is not yet available (Data Gap DG002), but based on well-established pharmacology, ribavirin is a guanosine nucleoside analog that inhibits IMPDH (inosine monophosphate dehydrogenase) and interferes with viral RNA polymerase / RNA-capping activity. This gives it broad activity against RNA viruses, and its only clinically validated use is in combination with peginterferon for chronic hepatitis C, which is an RNA virus.
Hepatitis B virus, by contrast, is a DNA virus that replicates via reverse transcriptase, not RNA-dependent RNA polymerase. This is a fundamental mechanistic mismatch: ribavirin’s core antiviral mechanism does not have a clear molecular target in HBV replication. Reviewing the retrieved clinical trial evidence confirms this concern — the large majority of trials tagged to this prediction are actually chronic hepatitis C trials (genotype 1, 2, 3, 4 HCV DAA/interferon combination studies), and several were flagged during grading as likely knowledge-graph mislabeling arising from the shared “chronic viral hepatitis” node neighborhood rather than true HBV studies.
That said, a small number of trials and one supporting publication (PMID 10832679, “Is ribavirin treatment really effective for chronic hepatitis B?”) directly address ribavirin/peginterferon-ribavirin use in genuine HBV populations, including one completed Phase 3 RCT (PARC study, NCT00114361) in HBeAg-negative chronic HBV. This keeps the signal from being a pure artifact, but it is not strong enough on its own to justify high confidence — the evidence base is dominated by co-infection and mislabeled HCV studies rather than a coherent HBV-specific efficacy signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00114361 | Phase 3 | Completed | 138 | PARC study: PegIFN alfa-2a + ribavirin vs. PegIFN monotherapy in HBeAg-negative chronic HBV — the only trial in the evidence set with an unambiguous HBV-monoinfection population. |
| NCT02339337 | Phase 4 | Completed | 203 | “Pioneer” study: tailored PegIFN alfa + ribavirin regimen in chronic Hepatitis C/Hepatitis B co-infected (HBeAg-negative) patients. |
| NCT00154869 | Phase 3 | Unknown | 320 | PegIFN alfa-2a + ribavirin in HCV/HBV co-infection vs. chronic HCV alone; treatment optimized primarily for the HCV component. |
| NCT01401400 | N/A | Completed | 1350 | GIANT-B study: genetic determinants of response to peginterferon (not ribavirin-specific) in chronic hepatitis B patients. |
| NCT02731131 | Phase 2 | Completed | 12 | PegIFN alfa-2a ± ribavirin in chronic Hepatitis D (HDV, a satellite virus dependent on HBV) — relevant to HBV-associated disease but not HBV monoinfection itself. |
| NCT00944684 | Phase 2 | Completed | 32 | PegIFN alfa-2a + serum-level-adapted vs. weight-based ribavirin, genotype 1 chronic hepatitis C — HBV relevance unconfirmed; flagged for manual verification. |
| NCT00378599 | Phase 3 | Completed | 125 | PROTECT study: PegIFN alfa-2b + ribavirin after liver transplant for hepatitis C recurrence — title suggests HCV, not HBV; flagged for verification. |
| NCT00630084 | Phase 4 | Completed | 120 | PegIFN + ribavirin outcomes in chronic hepatitis with concomitant malignancy — virus type (HBV vs. HCV) unclear from title alone. |
Note: the remaining ~55 trials returned by the search (e.g., NCT00637923, NCT01296451, NCT01852604) describe HCV-specific direct-acting antivirals, HCV vaccines, or HCV genotype studies and were assessed as likely mislabeled to this HBV prediction; they are omitted here as non-informative.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10832679 | 2000 | Review | J Gastroenterol | Directly addresses the question “Is ribavirin treatment really effective for chronic hepatitis B?” — most disease-specific reference in the evidence set. |
| 32664198 | 2020 | Review | Viruses | HCV/HBV co-infection review; notes pegIFN + ribavirin historically used for the HCV component in dual infection. |
| 24659886 | 2014 | Review | World J Gastroenterol | Treatment updates and outcomes in dual chronic HCV/HBV infection. |
| 27433078 | 2016 | Review | World J Gastroenterol | Reviews IFN-α ± ribavirin as prototype therapy for both HBV and HCV, contrasted with modern DAA approaches. |
| 19669238 | 2009 | Review | Hepatol Int | Overview of dual chronic HBV and HCV infection, viral interaction dynamics under treatment. |
| 18804888 | 2008 | Review | J Hepatol | Treatment of HBV/HCV co-infection described as “still a challenge for the hepatologist.” |
| 11160766 | 2001 | Review | Annu Rev Med | Current treatment strategies for chronic hepatitis B and C, contrasting IFN/lamivudine (HBV) with IFN/ribavirin (HCV). |
| 18414457 | 2008 | Review | Nat Clin Pract Gastroenterol Hepatol | Hepatitis B and C in children — treatment selection criteria discussed separately by virus type. |
| 17009938 | 2006 | Review | Expert Rev Anti Infect Ther | Treatment options for chronic hepatitis B and C in children. |
| 16838649 | 2006 | Case Report/Review | Nihon Rinsho | HCV-HBV infection overview (Japanese); confirms most effective IFN regimen is combined with ribavirin specifically for the HCV component. |
Note: nearly all retrieved literature discusses ribavirin’s established role in the HCV component of HBV/HCV co-infection, not as monotherapy or adjunct for HBV itself — this is a recurring pattern across the evidence set.
US Market Information
Ribavirin currently has no marketing authorization records in this dataset (market status: Not Marketed; 0 licenses on file). No NDA/product table can be generated from available data.
Safety Considerations
Please refer to the package insert for safety information. (TFDA label warnings/contraindications and DDI data are currently unavailable — see Data Gap DG001, marked Blocking severity.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted indication carries a high TxGNN score (99.86%, evidence level L2), but the supporting evidence is dominated by HCV or HCV/HBV co-infection studies where ribavirin’s role targets the HCV component — not a genuine HBV-specific efficacy signal. Only one trial (NCT00114361, PARC) and one publication (PMID 10832679) directly interrogate ribavirin’s effect in HBV monoinfection, and the mechanistic basis (RNA-virus-directed IMPDH inhibition applied to a DNA/reverse-transcriptase virus) is weak.
- The other nine predicted indications for this drug (rank 2–10, e.g., portal vein thrombosis, IgG4-related disease) have no supporting trials or literature and are assessed as likely knowledge-graph node-proximity artifacts rather than genuine repurposing candidates; none warrant further action at this time.
To proceed, the following is needed:
- Manual re-adjudication of the ~55 “pending”/Grade-C trials to confirm actual disease population (HBV vs. HCV) before counting them as supporting evidence
- Full-text review of the PARC study (NCT00114361) virologic outcome data to assess whether ribavirin added meaningful benefit over peginterferon monotherapy
- Confirmed DrugBank MOA record (DG002) to formally support or refute mechanistic plausibility for HBV
- TFDA package insert / label data (DG001, Blocking) before any safety-related decision can be made
- Clarification from the KG vendor on whether “chronic viral hepatitis” is being treated as a single node, which would explain the apparent HCV/HBV label bleed-through
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.